Abstract
Selective venous sampling catheterisation was performed in 19 patients with medullary thyroid carcinoma without known distant metastases for persistent hypercalcitoninaemia after surgery. Calcitonin (CT) gradients were found in the neck and/or the mediastinum in 18 patients and in five patients at distant sites also. After venous catheterisation, 13 patients were subjected to repeat surgery. Neck and/or mediastinal tumour foci were found in 12 patients at the sites of the CT gradients. Of these, nine patients had only cervicomediastinal CT gradients: after reoperation, the serum CT level normalised in one, significantly decreased in five, and did not change in three, and no neck relapse occurred after a mean follow-up of 5.3 years. Distant metastases emerged clinically in all five patients with distant gradients and in only one of the 14 patients with no distant gradient. In conclusion, selective venous catheterisation is the most sensitive tool for the localisation of residual disease and for the early detection of distant metastases. However, in patients with only local disease, biochemical cure is rarely obtained after reoperation.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ben Mrad M. D., Gardet P., Roche A., Rougier P., Calmettes C., Motte P., Parmentier C. Value of venous catheterization and calcitonin studies in the treatment and management of clinically inapparent medullary thyroid carcinoma. Cancer. 1989 Jan 1;63(1):133–138. doi: 10.1002/1097-0142(19890101)63:1<133::aid-cncr2820630121>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
- Calmettes C., Moukhtar M. S., Milhaud G. Calcitonine et antigène carcinoembryonnaires: marqueurs tumoraux au cours du cancer médullaire de la thyroïde. Presse Med. 1979 Dec 10;8(48):3947–3950. [PubMed] [Google Scholar]
- Frank-Raue K., Raue F., Buhr H. J., Baldauf G., Lorenz D., Ziegler R. Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization. Thyroid. 1992 Summer;2(2):113–117. doi: 10.1089/thy.1992.2.113. [DOI] [PubMed] [Google Scholar]
- Gautvik K. M., Talle K., Hager B., Jørgensen O. G., Aas M. Early liver metastases in patients with medullary carcinoma of the thyroid gland. Cancer. 1989 Jan 1;63(1):175–180. doi: 10.1002/1097-0142(19890101)63:1<175::aid-cncr2820630128>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
- Grauer A., Raue F., Gagel R. F. Changing concepts in the management of hereditary and sporadic medullary thyroid carcinoma. Endocrinol Metab Clin North Am. 1990 Sep;19(3):613–635. [PubMed] [Google Scholar]
- Motté P., Vauzelle P., Gardet P., Ghillani P., Caillou B., Parmentier C., Bohuon C., Bellet D. Construction and clinical validation of a sensitive and specific assay for serum mature calcitonin using monoclonal anti-peptide antibodies. Clin Chim Acta. 1988 May 13;174(1):35–54. doi: 10.1016/0009-8981(88)90365-8. [DOI] [PubMed] [Google Scholar]
- Tisell L. E., Hansson G., Jansson S., Salander H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery. 1986 Jan;99(1):60–66. [PubMed] [Google Scholar]
- van Heerden J. A., Grant C. S., Gharib H., Hay I. D., Ilstrup D. M. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg. 1990 Oct;212(4):395–401. doi: 10.1097/00000658-199010000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]